Shandong Sito Bio-technology Co Ltd

300583 · SHE · Healthcare / Biotechnology

11.09CNY-0.19 (-1.68%)

Price History

Full chart

Market Stats

Previous Close11.28

Open11.20

Day Range11.00 – 11.34

52-Week Range10.63 – 16.26

Volume2.65M

Market Cap2.60B

P/E (TTM)274.00

Forward P/E0.00

EPS0.05

Dividend Yield0.11%

Beta0.14

50-Day Avg12.89

200-Day Avg13.61

About

Shandong Sito Bio-technology Co., Ltd. researches, develops, and produces steroid biomedicine intermediates. Its products include 9a-hydroxyandrost, 17a-hydroxyprogesterone, 17a-hydroxy progesterone derivatives, anecort acetate, bis-decyl alcohol (BA), neomycin sulfate, progesterone intermediate, tylvalosin tartrate, tetraene acetate, androstenedione, bisnoralcohol, norandrostenedione, 16ß and 16a methyl epoxide, and hexahydro-3a-methyl, as well as androsta-1,4-diene-3,17-dione and estra-4,9-diene-3,17-dione. It also provides APIs for animal health, including neomycin sulfate and tylosin tartrate. Shandong Sito Bio-technology Co., Ltd. was founded in 2002 and is based in Heze, China.

Company Details

SectorHealthcare
IndustryBiotechnology
CEOMr. Qi Mi
Employees990
HeadquartersSouth section of East Outer Ring Road,, Heze, China, 274100, China
Websitehttps://www.sitobiotech.com

Leadership

Mr. Qi MiChairman & GM · b. 1990
Mr. Fuwen LiChief Financial Officer · b. 1976
Ms. Lu LiDeputy GM, Board Secretary & Director · b. 1977
Yong Hong WangAccounting Supervisor

Financials

Income Statement

Currency: CNY	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	11.03M	283.59M	521.01M	668.17M	568.25M	785.57M	1.05B	965.80M	913.19M	1.20B	1.31B	1.28B	970.60M	1.02B
Growth (%)	-	+2470.70%	+83.72%	+28.24%	-14.95%	+38.24%	+33.95%	-8.22%	-5.45%	+31.70%	+9.10%	-2.46%	-24.16%	+4.77%
Cost of Revenue	9.02M	199.50M	278.94M	373.91M	377.69M	602.94M	787.94M	736.24M	814.07M	956.55M	1.05B	1.01B	862.50M	864.32M
Gross Profit	2.01M	84.08M	242.07M	294.26M	190.56M	182.62M	264.34M	229.56M	99.12M	246.07M	261.44M	268.31M	108.10M	152.55M
Gross Margin	18.24%	29.65%	46.46%	44.04%	33.53%	23.25%	25.12%	23.77%	10.85%	20.46%	19.93%	20.97%	11.14%	15.00%
Operating Expense	3.64M	29.16M	46.12M	76.02M	76.15M	79.38M	115.19M	162.37M	285.28M	190.10M	212.22M	235.57M	210.16M	149.05M
Operating Income	-1.63M	54.92M	195.95M	218.23M	114.41M	103.24M	149.15M	67.19M	-186.16M	55.97M	49.22M	32.74M	-102.06M	3.50M
Operating Margin	-14.76%	19.37%	37.61%	32.66%	20.13%	13.14%	14.17%	6.96%	-20.39%	4.65%	3.75%	2.56%	-10.52%	0.34%
EBITDA	-430.58K	64.50M	218.71M	266.60M	173.43M	170.45M	237.53M	181.63M	-14.07M	219.11M	247.63M	263.92M	102.19M	119.70M
EBITDA Margin	-3.90%	22.75%	41.98%	39.90%	30.52%	21.70%	22.57%	18.81%	-1.54%	18.22%	18.87%	20.62%	10.53%	11.77%
Net Income	-1.49M	41.56M	165.75M	187.04M	101.18M	92.00M	126.09M	55.31M	-179.81M	36.21M	41.97M	45.60M	-88.77M	-73.15M
Net Income Margin	-13.53%	14.66%	31.81%	27.99%	17.81%	11.71%	11.98%	5.73%	-19.69%	3.01%	3.20%	3.56%	-9.15%	-7.19%
R&D	374.00K	10.09M	16.82M	22.67M	19.15M	31.66M	39.42M	55.79M	45.01M	49.73M	50.21M	55.08M	58.38M	41.54M
R&D as % of Total Revenue	3.39%	3.56%	3.23%	3.39%	3.37%	4.03%	3.75%	5.78%	4.93%	4.14%	3.83%	4.30%	6.01%	4.09%
Interest Expense	821.38K	5.99M	8.56M	14.54M	13.32M	7.52M	20.70M	34.28M	35.51M	31.57M	38.88M	40.86M	35.23M	29.03M
Interest Expense % of Total Revenue	7.45%	2.11%	1.64%	2.18%	2.34%	0.96%	1.97%	3.55%	3.89%	2.63%	2.96%	3.19%	3.63%	2.85%

Balance Sheet

Currency: CNY	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	59.98M	210.66M	507.11M	838.28M	936.23M	2.02B	2.59B	2.99B	2.84B	2.97B	3.00B	3.24B	3.03B	2.96B
Total Liabilities	27.51M	111.83M	216.31M	331.62M	333.22M	317.42M	732.63M	1.10B	1.15B	1.24B	1.22B	1.17B	1.14B	1.16B
Total Equity	32.47M	98.83M	290.80M	478.52M	579.69M	1.69B	1.81B	1.83B	1.64B	1.68B	1.72B	2.01B	1.84B	1.76B
Cash	52.42K	12.86M	23.08M	90.41M	33.51M	310.92M	119.32M	183.61M	344.50M	161.50M	188.40M	238.49M	255.96M	295.07M
Total Debt	-	75.19M	135.00M	200.00M	234.40M	150.00M	494.70M	751.76M	658.06M	671.17M	699.95M	742.60M	722.16M	-
Net Debt	-52.42K	62.33M	111.92M	109.59M	200.89M	-160.92M	375.38M	568.15M	313.56M	509.67M	511.55M	504.11M	466.19M	448.29M

Cash Flow

Currency: CNY	2012-12-31	2013-12-31	2014-12-31	2015-12-31	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	-30.50M	24.95M	174.49M	87.10M	80.15M	10.90M	-334.41M	57.62M	254.60M	227.35M	145.34M	-92.85M	194.46M	158.53M
Investing Cash Flow	-8.53M	-90.63M	-218.25M	-138.62M	-117.88M	-658.55M	-223.93M	13.17M	-29.23M	-361.48M	-140.74M	-103.78M	-57.31M	-
Financing Cash Flow	38.22M	73.49M	52.84M	80.97M	19.51M	912.39M	344.87M	8.98M	-140.73M	-47.67M	-4.99M	319.77M	-163.04M	-
Capital Expenditure	10.37M	46.55M	229.42M	130.67M	125.87M	75.34M	220.86M	210.73M	242.60M	388.92M	143.68M	94.06M	65.53M	79.65M
Free Cash Flow	-40.87M	-21.60M	-54.93M	-43.56M	-45.72M	-64.44M	-555.27M	-153.12M	12.00M	-161.57M	1.66M	-186.90M	128.93M	78.88M
Dividends Paid	-	5.51M	6.40M	11.03M	13.89M	14.73M	24.77M	15.07M	5.51M	24.52M	1.60M	32.28M	112.85M	27.76M
FCF to OCF	133.98%	-86.58%	-31.48%	-50.01%	-57.05%	-591.44%	166.04%	-265.75%	4.71%	-71.07%	1.14%	201.31%	66.30%	49.76%
Dividend Paid to FCF	-	-25.52%	-11.66%	-25.31%	-30.37%	-22.85%	-4.46%	-9.84%	45.90%	-15.17%	96.67%	-17.27%	87.53%	35.20%

Earnings

Report Date	Apr 25, 2017	Aug 28, 2017	Oct 26, 2017	Dec 31, 2017	Apr 22, 2018	Jun 30, 2018	Sep 30, 2018	Dec 31, 2018	Mar 31, 2019	Jun 30, 2019	Sep 30, 2019	Dec 31, 2019	Apr 29, 2020	Aug 28, 2020	Oct 30, 2020	Dec 31, 2020	Apr 20, 2021	Jun 30, 2021	Sep 30, 2021	Dec 31, 2021	Mar 31, 2022	Jun 30, 2022	Sep 30, 2022	Dec 31, 2022	Mar 31, 2023	Jun 30, 2023	Sep 30, 2023	Dec 31, 2023	Jun 21, 2024	Jun 30, 2024	Sep 30, 2024	Dec 31, 2024	Jun 20, 2025	Jun 30, 2025	Sep 30, 2025	Dec 31, 2025	Mar 31, 2026	Jun 30, 2026
EPS Estimate	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
EPS Actual	0.04	0.22	0.16	0.27	0.28	0.24	0.17	0.16	0.19	0.18	0.12	-0.16	-0.23	-0.12	-0.11	-0.76	-0.05	0.14	0.07	0.03	0.07	0.11	0.05	0.00	0.09	0.25	0.01	-0.08	0.02	0.05	0.01	-0.55	-0.14	-0.13	-0.09	-0.02	0.02	0.14
Surprise	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Timing	Pre-market	After-hours	After-hours	-	After-hours	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	After-hours	-	-	-	After-hours	-	-	-	-	-

Key Statistics & Ratios

Market Cap2.60B

Enterprise Value3.09B

Trailing P/E274.00

Forward P/E0.00

Price / Sales2.32

Price / Book1.49

EPS0.05

Book Value9.29

Revenue (TTM)1.12B

Gross Profit (TTM)229.25M

EBITDA219.26M

Profit Margin0.87%

Operating Margin12.32%

Return on Equity0.34%

Return on Assets1.13%

Shares Outstanding189.70M

Shares Float99.67M

Beta0.14

Dividend Yield0.11%

Dividend Rate0.02

Payout Ratio9.69%

Dividends

20261×

0.01Jul 14, 2026

20252×

0.01Sep 24, 20250.01Jun 20, 2025

20241×

0.45Jul 30, 2024

20231×

0.01Jun 28, 2023

20221×

0.01Jul 5, 2022

20201×

0.03Jun 24, 2020

20191×

0.09Jun 13, 2019

20181×

0.06Jun 28, 2018

20171×

0.06Jun 27, 2017

Stock Splits

Aug 25, 20231.6:1